Nichi-Iko buys into Korean biosimilar capacity
This article was originally published in Scrip
Nichi-Iko Pharmaceutical, one of Japan's largest generics firms, has acquired a 12.6% equity stake in Binex, a South Korean contract manufacturer, in an alliance it says will focus on the production of biosimilars.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.